• M. Herden
  • Cornelius F. WallerEmail author
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 211)


Alectinib is an ATP-competitive small molecule and a second-generation inhibitor of ALK. EML4-ALK rearrangement is found in 3–5% of patients with NSCLC. The first-generation inhibitor crizotinib has changed the treatment dramatically, though most of the patients show disease progression within one year. Extra-thoracic progress, i.e., CNS metastases is common. The second-generation inhibitor alectinib has shown significant improvement in PFS and a remarkable prolongation of time to CNS progression. Alectinib has received approval as first-line therapy as well as second-line therapy after crizotinib failure. The toxicity profile is favorable compared to crizotinib and chemotherapy.


Alectinib EML4-ALK ALK-inhibitor NSCLC CNS metasteses 


  1. Awad MM, Shaw AT (2014) ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol 12:429–439PubMedPubMedCentralGoogle Scholar
  2. Costa DB et al (2015) Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 33:1881–1888CrossRefPubMedPubMedCentralGoogle Scholar
  3. Dacic S et al (2016) ALK fish patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma. Oncotarget. Scholar
  4. Gadgeel SM et al (2014) Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 15:1119–1128CrossRefPubMedGoogle Scholar
  5. Gainor JF, Yoda S et al (2016) Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 6(10):1118–1133Google Scholar
  6. Gainor JF et al (2017) Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non-small-cell lung cancer. JCO Precis Oncol. Available at: Accessed: 4th Dec 2017
  7. Hida T et al (2017) Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 390:29–39CrossRefPubMedGoogle Scholar
  8. Kinoshita K et al (2011) 9-Substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors. J Med Chem 54:6286–6294CrossRefPubMedGoogle Scholar
  9. Kinoshita K et al (2012) Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802). Bioorg Med Chem 20:1271–1280CrossRefPubMedGoogle Scholar
  10. Kodama T et al (2014a) Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. Mol Cancer Ther 13:2910–2918CrossRefPubMedGoogle Scholar
  11. Kodama T et al (2014b) Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol 74:1023–1028CrossRefPubMedGoogle Scholar
  12. Kodama T, Tsukaguchi T, Yoshida M, Kondoh O, Sakamoto H (2014c) Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett 351:215–221CrossRefPubMedGoogle Scholar
  13. Morcos PN et al (2017) Clinical drug-drug interactions through cytochrome P450 3A (CYP3A) for the selective ALK inhibitor alectinib. Clin Pharmacol Drug Dev 6:280–291CrossRefPubMedGoogle Scholar
  14. Muller IB, De Langen AJ, Honeywell RJ, Giovannetti E, Peters GJ (2016) Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib. Expert Rev Anticancer Ther 16:147–157CrossRefPubMedGoogle Scholar
  15. Nakagawa T et al (2017) In vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes. Xenobiotica 1–9.
  16. Nanjo S et al (2015) In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line. Cancer Sci 106:244–252CrossRefPubMedPubMedCentralGoogle Scholar
  17. Ou S-HI et al (2016) Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol 34:661–668CrossRefPubMedGoogle Scholar
  18. Park HS et al (2012) Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer 77:288–292CrossRefPubMedGoogle Scholar
  19. Peled N et al (2012) Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol 7:e14–e16CrossRefPubMedPubMedCentralGoogle Scholar
  20. Peters S et al (2017) Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 377:829–838CrossRefPubMedGoogle Scholar
  21. Sakamoto H et al (2011) CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 19:679–690CrossRefPubMedGoogle Scholar
  22. Seto T et al (2013) CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study. Lancet Oncol 14:590–598CrossRefPubMedGoogle Scholar
  23. Shaw AT et al (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385–2394CrossRefPubMedGoogle Scholar
  24. Shaw AT et al (2016) Alectinib in ALK -positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 17:234–242CrossRefPubMedGoogle Scholar
  25. Soda M et al (2007) Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature 448:561–566CrossRefPubMedGoogle Scholar
  26. Solomon BJ, Mok T, Kim DW et al (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167–2177CrossRefPubMedGoogle Scholar
  27. Song Z, Wang M, Zhang A (2015) Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance. Acta Pharm Sinica B 5:34–37CrossRefGoogle Scholar
  28. Sullivan I, Planchard D (2016) ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol 8:32–47CrossRefPubMedPubMedCentralGoogle Scholar
  29. Webb TR et al (2009) Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther 9:331–356CrossRefPubMedPubMedCentralGoogle Scholar
  30. Wolf J et al (2016) ALUR: a phase 3 study of alectinib versus chemotherapy in previously treated ALK+ non-small cell lung cancer (NSCLC). Ann Oncol 27Google Scholar
  31. Yang K et al (2017) Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo. Exp Mol Med 49:e303CrossRefPubMedPubMedCentralGoogle Scholar
  32. Yoshida T et al (2016) Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer. Lung Cancer 97:43–47CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Haematology, Oncology and Stem Cell Transplantation, University Medical Centre Freiburg, Faculty of MedicineUniversity of FreiburgFreiburgGermany

Personalised recommendations